Cargando…

Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy

Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells is an attractive research field in tumor immunotherapy. While CAR is genetically engineered to express certain molecules, it retains the intrinsic ability to recognize tumor cells through its own receptors. Additionally, NK cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Kangdi, Zhao, Yuze, Sun, Guanqun, Zhang, Xu, Cao, Jinjin, Shao, Mingcong, Liang, Xijun, Wang, Lina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892943/ https://www.ncbi.nlm.nih.gov/pubmed/36741400 http://dx.doi.org/10.3389/fimmu.2022.1081546

Ejemplares similares

NK Cell Dysfunction and Checkpoint Immunotherapy
por: Bi, Jiacheng, et al.
Publicado: (2019)

Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Yang, Guanqun, et al.
Publicado: (2022)

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
por: Zhang, Cai, et al.
Publicado: (2020)

TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Qiu, Hui, et al.
Publicado: (2021)

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
por: Cifaldi, Loredana, et al.
Publicado: (2023)

Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer
por: Sivori, Simona, et al.
Publicado: (2020)

The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy
por: Sun, Haoyu, et al.
Publicado: (2019)

NK Cell-Based Immune Checkpoint Inhibition
por: Khan, Muhammad, et al.
Publicado: (2020)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

Prospects for NK-based immunotherapy of chronic HBV infection
por: Jin, Xiaomeng, et al.
Publicado: (2022)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
por: Burger, Michael C., et al.
Publicado: (2019)

On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies
por: Ward, Frank J., et al.
Publicado: (2018)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Diversity of immune checkpoints in cancer immunotherapy
por: Guo, Zhangyan, et al.
Publicado: (2023)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
por: Perrino, Matteo, et al.
Publicado: (2023)

CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma
por: Ciulean, Ioana Sonya, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
por: Heim, Catrin, et al.
Publicado: (2023)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

CAR-NK Cells: From Natural Basis to Design for Kill
por: Khawar, Muhammad Babar, et al.
Publicado: (2021)

Overcoming tumor resistance mechanisms in CAR-NK cell therapy
por: Valeri, Antonio, et al.
Publicado: (2022)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy
por: Yang, Mingya, et al.
Publicado: (2021)

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
por: Wu, Jianmin, et al.
Publicado: (2021)

Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation
por: Dumolard, Lucile, et al.
Publicado: (2023)

Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology
por: Hercun, Julian, et al.
Publicado: (2022)

The role of neurologists in the era of cancer immunotherapy: Focus on CAR T-cell therapy and immune checkpoint inhibitors
por: Pensato, Umberto, et al.
Publicado: (2022)

Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors
por: Yu, Tao, et al.
Publicado: (2022)

CAR-NK cells: A promising cellular immunotherapy for cancer
por: Xie, Guozhu, et al.
Publicado: (2020)

Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy
por: Xu, Shumin, et al.
Publicado: (2023)

HLA Class I Molecules as Immune Checkpoints for NK Cell Alloreactivity and Anti-Viral Immunity in Kidney Transplantation
por: Duygu, Burcu, et al.
Publicado: (2021)

Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence
por: Ahmetlic, Fatima, et al.
Publicado: (2021)

Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions
por: Wurster, Sebastian, et al.
Publicado: (2022)

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
por: Jiang, Jingyu, et al.
Publicado: (2023)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2ph0bsip0jef4j1umuvnipj5n1